Gregory Alan Korbel, VP of Business Dev't at Aprea Therapeutics, Inc. (APRE), bought 500 shares at $15.00 ($8K) on 2019-10-07, disclosed to the SEC on 2019-10-07.
Open-market purchase of $8k APRE by VP of Business Dev't. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| APRE | SELL | 2021-10-05 | $134K | — | Filing → |
| APRE | SELL | 2021-09-22 | $164K | — | Filing → |